Heterologous ChAdOx1 nCoV-19/BNT162b2 Prime-Boost Vaccination Induces Strong Humoral Responses among Health Care Workers

被引：54

作者：

Benning, Louise ^{[1
]}

Toellner, Maximilian ^{[1
]}

Hidmark, Asa ^{[1
]}

Schaier, Matthias ^{[1
]}

Nusshag, Christian ^{[1
]}

Kaelble, Florian ^{[1
]}

Reichel, Paula ^{[1
]}

Buylaert, Mirabel ^{[1
]}

Grenz, Julia ^{[1
]}

Ponath, Gerald ^{[1
]}

Klein, Katrin ^{[1
]}

Zeier, Martin ^{[1
]}

Susal, Caner ^{[2
]}

Schnitzler, Paul ^{[3
]}

Morath, Christian ^{[1
]}

Speer, Claudius ^{[1
,4
]}

机构：

[1] Univ Heidelberg Hosp, Dept Nephrol, D-69120 Heidelberg, Germany

[2] Univ Heidelberg Hosp, Inst Immunol, D-69120 Heidelberg, Germany

[3] Univ Heidelberg Hosp, Dept Infect Dis Virol, D-69120 Heidelberg, Germany

[4] EMBL, Mol Med Partnership Unit Heidelberg, D-69117 Heidelberg, Germany

来源：

VACCINES | 2021年 / 9卷 / 08期

关键词：

COVID-19; vaccination; heterologous vaccination; humoral response; mRNA vaccine; BNT162b2; adenovirus-vectored vaccine; ChAdOx1; nCoV-19; SARS-CoV-2;

D O I：

10.3390/vaccines9080857

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Despite limited data on safety and immunogenicity, heterologous prime-boost vaccination is currently recommended for individuals with ChAdOx1 nCoV-19 prime immunization in certain age groups. In this prospective, single-center study we included 166 health care workers from Heidelberg University Hospital who received either heterologous ChAdOx1 nCoV-19/BNT162b2, homologous BNT162b2 or homologous ChAdOx1 nCoV-19 vaccination between December 2020 and May 2021. We measured anti-S1 IgG, SARS-CoV-2 specific neutralizing antibodies, and antibodies against different SARS-CoV-2 fragments 0-3 days before and 19-21 days after boost vaccination. Before boost, 55/70 (79%) ChAdOx1 nCoV-19-primed compared with 44/45 (98%) BNT162b2-primed individuals showed positive anti-S1 IgG with a median (IQR) anti-S1 IgG index of 1.95 (1.05-2.99) compared to 9.38 (6.26-17.12). SARS-CoV-2 neutralizing antibodies exceeded the threshold in 24/70 (34%) of ChAdOx1 nCoV-19-primed and 43/45 (96%) of BNT162b2-primed individuals. After boosting dose, median (IQR) anti-S1 IgG index in heterologous ChAdOx1 nCoV-19/BNT162b2 vaccinees was 116.2 (61.84-170), compared to 13.09 (7.03-29.02) in homologous ChAdOx1 nCoV-19 and 145.5 (100-291.1) in homologous BNT162b2 vaccinees. All boosted vaccinees exceeded the threshold for neutralization, irrespective of their vaccination scheme. Vaccination was well-tolerated overall. We show that heterologous ChAdOx1 nCoV-19/BNT162b2 vaccination is safe and induces a strong and broad humoral response in healthy individuals.

引用

页数：13

共 23 条

[1] Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination [J].

Barros-Martins, Joana ;

Hammerschmidt, Swantje, I ;

Cossmann, Anne ;

Odak, Ivan ;

Stankov, Metodi, V ;

Ramos, Gema Morillas ;

Dopfer-Jablonka, Alexandra ;

Heidemann, Annika ;

Ritter, Christiane ;

Friedrichsen, Michaela ;

Schultze-Florey, Christian ;

Ravens, Inga ;

Willenzon, Stefanie ;

Bubke, Anja ;

Ristenpart, Jasmin ;

Janssen, Anika ;

Ssebyatika, George ;

Bernhardt, Gunter ;

Muench, Jan ;

Hoffmann, Markus ;

Poehlmann, Stefan ;

Krey, Thomas ;

Bosnjak, Berislav ;

Foerster, Reinhold ;

Behrens, Georg M. N. .

NATURE MEDICINE, 2021, 27 (09) :1525-+

[2]

Borobia A.M., REACTOGENICITY IMMUN

[3] Development and Validation of a Multiplex, Bead-based Assay to Detect Antibodies Directed Against SARS-CoV-2 Proteins [J].

Bray, Robert A. ;

Lee, Jar-How ;

Brescia, Peter ;

Kumar, Deepali ;

Nong, Thoa ;

Shih, Remi ;

Woodle, E. Steve ;

Maltzman, Jonathan S. ;

Gebel, Howard M. .

TRANSPLANTATION, 2021, 105 (01) :79-89

[4] Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection [J].

Dan, Jennifer M. ;

Mateus, Jose ;

Kato, Yu ;

Hastie, Kathryn M. ;

Yu, Esther Dawen ;

Faliti, Caterina E. ;

Grifoni, Alba ;

Ramirez, Sydney, I ;

Haupt, Sonya ;

Frazier, April ;

Nakao, Catherine ;

Rayaprolu, Vamseedhar ;

Rawlings, Stephen A. ;

Peters, Bjoern ;

Krammer, Florian ;

Simon, Viviana ;

Saphire, Erica Ollmann ;

Smith, Davey M. ;

Weiskopf, Daniela ;

Sette, Alessandro ;

Crotty, Shane .

SCIENCE, 2021, 371 (6529) :587-+

[5] Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination [J].

Greinacher, Andreas ;

Thiele, Thomas ;

Warkentin, Theodore E. ;

Weisser, Karin ;

Kyrle, Paul A. ;

Eichinger, Sabine .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (22) :2092-2101

[6]

Grobeta

[7]

R., Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity, P2021, DOI DOI 10.1101/2021.05.30.21257971

[8] Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study [J].

Hillus, David ;

Schwarz, Tatjana ;

Tober-Lau, Pinkus ;

Vanshylla, Kanika ;

Hastor, Hana ;

Thibeault, Charlotte ;

Jentzsch, Stefanie ;

Helbig, Elisa T. ;

Lippert, Lena J. ;

Tscheak, Patricia ;

Schmidt, Marie Luisa ;

Riege, Johanna ;

Solarek, Andre ;

von Kalle, Christof ;

Dang-Heine, Chantip ;

Gruell, Henning ;

Kopankiewicz, Piotr ;

Suttorp, Norbert ;

Drosten, Christian ;

Bias, Harald ;

Seybold, Joachim ;

Klein, Florian ;

Kurth, Florian ;

Corman, Victor Max ;

Sander, Leif Erik .

LANCET RESPIRATORY MEDICINE, 2021, 9 (11) :1255-1265

[9] Sex differences in immune responses [J].

Klein, Sabra L. ;

Flanagan, Katie L. .

NATURE REVIEWS IMMUNOLOGY, 2016, 16 (10) :626-638

[10] Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine [J].

Krammer, Florian ;

Srivastava, Komal ;

Simon, Viviana .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (14) :1372-1374

← 1 2 3 →